Enveric Biosciences to Submit Investigational New Drug Application for Depression Medication
MT Newswires Live
Sep 16
Enveric Biosciences (ENVB) said Tuesday that it will streamline its regulatory pathway and proceed to an Investigational New Drug, or IND, application, for its depression and anxiety treatment candidate, EB-003.
The company said it expects to file the IND application in early 2026.
Enveric said that in response to its Pre-Investigational New Drug Type B meeting request to the FDA, the regulator indicated that the company's queries were a matter for review under an IND application and recommended that it proceed with the submission.
Shares of the company were up 1.1% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.